So the theory that these jabs only give sore arms is a bit ridiculous.
Thrombo-embolic events with concurrent low platelets
Up to 21 April 2021, the MHRA had received Yellow Card reports of 209 cases of major thromboembolic events (blood clots) with concurrent thrombocytopenia (low platelet counts) in the UK following vaccination with COVID-19 Vaccine AstraZeneca.
These events occurred in 120 women and 89 men aged from 18 to 93 years and the overall case fatality rate was 19% with 41 deaths. Four cases have been reported after a second dose. Cerebral venous sinus thrombosis was reported in 84 cases (average age 47 years) and 123 had other major thromboembolic events (average age 55 years) with concurrent thrombocytopenia. Diagnosis was unclear in the remaining two cases.
The estimated number of first doses of COVID-19 Vaccine AstraZeneca administered in the UK by 21 April was 22 million giving an overall case incidence of 9.3 per million doses. The data suggest there is a higher incidence reported in the younger adult age groups and the MHRA advises that this evolving evidence should be taken into account when considering the use of the vaccine.